Answers are grounded in this paper and cite their sources.
Cyclic GMP-AMP synthase (cGAS) plays an important role in inducing innate immune responses necessary for defense against invading pathogens and for repair of internal tissue damage.However, excessive accumulation of intracellular double-stranded DNA (dsDNA) leading to overactivation of cGAS results in a variety of chronic diseases including autoimmune disorders and inflammatory diseases.Therefore, a specific cGAS inhibitor can be utilized as an efficient therapeutic strategy for the prevention or treatment of chronic inflammatory diseases.We found that butaclamol inhibited cGAS activation induced by dsDNA by IFN-stimulated response elements-dependent luciferase reporter assay.Butaclamol reduced dsDNA-induced generation of 2'3'-cGAMP, of which production is dependent on cGAS enzymatic activity.Butaclamol did not suppress a STING agonist-induced luciferase reporter gene expression.The results suggest that butaclamol inhibits cGAS, but not STING.The inhibition of cGAS activation by butaclamol culminated in the reduction of cGAS-target gene, IFN-β.Butaclamol did not inhibit IFN-β production induced by agonists of other pattern-recognition receptors, suggesting that the inhibitory effect of butaclamol is rather specific for cGAS.Our results present butaclamol as a novel cGAS inhibitor and further suggest the possibility for therapeutic potential of butaclamol in prevention and treatment of cGAS-related immune diseases.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: